4SC announces update relating to Resminostat’s (Kinselby) Marketing Authorisation Application
Planegg-Martinsried, Germany, 7 January 2025 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that it had submitted its responses to the Day-120 List of Questions from the European Medicines Agency (EMA) in December 2024 as planned, following 4SC’s initial […]
